Briefing: How Health Systems Will Manage Biosimilars: Implications for Manufacturers
Precision for Value’s Jeremy Schafer discusses managing biosimilars and the implications for health systems in a new article for Biosimilars Development.
Unique Methodologies Help Meet Reimbursement Requirements for Oncology Treatment in European Countries
Citing concerns about the methods used to estimate overall survival, a European payer objected to the reimbursement cost-effectiveness analysis submitted by an oncology product manufacturer. Learn how a global systematic literature review and meta-analysis provided a platform for a compelling response.
Tomas Philipson Participates in AEI Panel on Pricing of Specialty Drugs
On Monday, September 12th, 2016 at AEI, health policy experts representing practitioners and industry discussed the issue of high drug prices.
On the panel, Precision Health Economics’ Tomas Philipson cast doubt on the claim that research and development determine pricing, arguing that in reality causality runs in the opposite direction. He noted potential flaws in value-based pricing and a one-size-fits-all-approach to global drug development and argued for more robust credit markets in health care.
Commentary: Value Frameworks Are Here: What To Do About Them?
Precision Health Economics’ Senior Research Economist Jason Shafrin provides an in-depth analysis of value frameworks in a new article for Pharmaceutical Commerce.
Commentary: To Prevent Another EpiPen Controversy, the Government Should Step In
Precision Health Economics’ Dana Goldman addresses the firestorm created by Mylan’s dramatic price hikes for their EpiPen in a new commentary published in STAT News: “To Prevent Another EpiPen Controversy, the Government Should Step In.”
Commentary: Concierge Care Can Help Indigent Uninsured
Precision Health Economics’ Dana Goldman offers his latest opinion piece for the New York Times,”Hospital Care for Those Who Can Afford It Helps Care for Those Who Can’t.” In his commentary, Dr. Goldman suggests that concierge care may paradoxically be the best hope for ensuring continued access to healthcare for the indigent uninsured.
Biosimilar Expert Schafer Interviewed for BioPharm Insight
Precision for Value thought leader Jeremy Schafer was recently interviewed by BioPharm Insight’s Reynald Castaneda, providing his perspective into projected competition in the biosimilar marketplace.
Commentary: Anti-TNF Biosimilars In Europe: What Matters Beyond Price?
In the latest edition of Life Science Leader, Precision’s Andre Pinheiro, Mansi Vithlani, Kyle Sarnataro, and Alex Grosvenor examine the introduction of Anti-TNF Biosimilars in Europe.
Commentary: New Value Frameworks Miss the Point
In his latest Forbes.com commentary, Precision Health Economics co-founder Tomas Philipson (along with Precision co-author Jason Shafrin) addresses the development of new value frameworks, and how both physicians and patients are at risk.
Insider Q&A: A Model for More Rational Drug Prices – Associated Press
Precision Health Economics’ Darius Lakdawalla speaks with the AP’s Matthew Perrone and offers some guidelines for drug pricing.